Trial for Bundibugyo Ebola treatment starts in DRC, WHO says
⚡ Quick Summary
The trial will evaluate Mapp Biopharmaceutical's experimental MBP134 antibody as a standalone treatment for Bundibugyo Ebola, as well as in combination with Gilead Sciences' antiviral drug remdesivir, the WHO said
🗞️ 2 sources covered this story
📰 Related Articles
Atiku challenges FG over IMF’s ‘missing 2% GDP’, seeks probe
Punch Nigeria
Bauchi gets N10bn maternal, newborn healthcare intervention
Punch Nigeria
WATCH: Eagle-eye view of the Great American Fair
ABC News
'Academic jihad': BJP seeks ban on J K textbook 'glorifying terrorists'; LG suspends 8
Times of India
Woman held for cheating, blackmailing real estate entrepreneur
The Hindu